Potential benefits of icosapent ethyl on the lipid profile: Case studies

Clinical Medicine Insights: Cardiology

Volumn 8, Issue , 2014, Pages 13-15

  Hilleman, Daniel E ^a   Malesker, Mark A ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF PHARMACY AND HEALTH PROFESSIONS   (United States)

Author keywords

Docosahexaenoic acid; Eicosapentaenoic acid; Fish oil; Icosapent ethyl; Lipids; Omega 3 fatty acids

Indexed keywords

AMLODIPINE; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARLSON EPA GEMS; CHOLESTEROL; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCHLOROTHIAZIDE; ICOSAPENTAENOIC ACID ETHYL ESTER; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; METOPROLOL XL; OMEGA 3 ACID ETHYL ESTER; RAMIPRIL; SAXAGLIPTIN; TELMISARTAN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CASE REPORT; CHOLESTEROL BLOOD LEVEL; DIET SUPPLEMENTATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; MALE; MEDICATION COMPLIANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOARTHRITIS; UNSPECIFIED SIDE EFFECT;

EID: 84893560587     PISSN: 11795468     EISSN: 11795468     Source Type: Journal    
DOI: 10.4137/CMC.s13571     Document Type: Article

References (22)

1. Yokoyama M, Origasa H, Matsuzaki M, etal. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369:1090-8.
2. GISSI Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet. 1999;354:447-55.
3. GISSI-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1223-30.
4. Bays H. Fish oils in the treatment of dyslipidemia and cardiovascular disease. In: Kwiterovich PO, ed. The Johns Hopkins Textbook of Dyslipidemia. Philadelphia, PA: Lippincott Williams and Wolters Kluwer; 2010:245-57.
5. Lavie CJ, Milani RV, Mehra MR, Ventura HO. Omega-3 polyunsaturated fatty acids and cardiovascular diseases. J Am Coll Cardiol. 2009;54:585-94.
6. Kris-Etherton PM, Harris WS, Appel LJ. Omega-3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association. Arterioscler Thromb Vasc Biol. 2003;23:151-2.
7. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002;106:2747-57.
8. Lovaza [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2013.
9. Vascepa [package insert]. Bedminster, NJ: Amarin Pharma Inc.; 2013.
10. Balk EM, Lichtenstein AH, Chung M, Kupelnick B, Chew P, Lau J. Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis. 2006;189:19-30.
11. Skulas-Ray AC, West SG, Davidson MH, Kris-Etherton PM. Omega-3 fatty acid concentrates in the treatment of moderate hypertriglyceridemia. Expert Opin Pharmacother. 2008;9:1237-48.
12. Wei MY, Jacobson TA. Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis. Curr Atheroscler Rep. 2011;13:474-83.
13. Jacobson TA, Glickstein SB, Rowe JD, Soni PN. Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review. J Clin Lipidol. 2012;6:5-18.
14. Tatsuno I, Saito Y, Kudou K, Ootake J. Efficacy and safety of TAK-085 compared with eicosapentaenoic acid in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: the Omega-3 fatty acids Randomized Double-blind (ORD) study. J Clin Lipidol. 2013;7:199-207.
15. Evert AB, Boucher JL, Cypress M, etal. Nutrition therapy recommendations for the management of adults with diabetes. Diabetes Care. 2013;36:3821-42.
16. A study of AMR101 to evaluate its ability to reduce cardiovascular events in high-risk patients with hypertriglyceridemia and on statins (REDUCE-IT); NCT01492361. Amarin Pharma Inc. Available at: http://clinicaltrials.gov/ct2/show/NCT01492361?term = AMR101&rank = 3. Accessed December 5, 2013.
17. EPA Gems Supplemental Facts. Carlson Laboratories. Available at: http://www.carlsonlabs.com/p-189-epa-gems.aspx. Accessed December 5, 2013.
18. Collins N, Tighe AP, Brunton SA, Kris-Etherton PM. Differences between dietary supplement and prescription drug omega-3 fatty acid formulations: a legislative and regulatory perspective. J Am Coll Nutr. 2008;27:659-66.
19. Fish oil and omega-3 fatty acid supplements (EPA and DHA from fish, algae, and krill). Consumer Lab. Available at: https://www.consumerlab.com/reviews/fish_oil_supplements_review/omega3/. Accessed December 5, 2013.
20. Food and Drug Administration. Overview of dietary supplements. Food and Drug Administration. Available at: http://www.fda.gov/Food/DietarySupplements/ConsumerInformation/ucm110417.htm?utm_campaign=Google2&utm_source=fdaSearch&utm_medium=website&utm_term=dietary. Accessed December 5, 2013.
21. Lovaza Pricing Information. Truven Health Analytics. Available at: http://www.redbook.com/redbook/. Accessed December 5, 2013.
22. Vascepa Pricing Information. Truven Health Analytics. Available at: http://www.redbook.com/redbook/. Accessed December 5, 2013.